ProQR Therapeutics (PRQR) Income from Non-Controlling Interests (2016 - 2023)

ProQR Therapeutics (PRQR) has reported Income from Non-Controlling Interests for 8 consecutive years, with $330006.7 the latest figure, recorded in Q3 2023.

• Quarterly Income from Non-Controlling Interests rose 1971.43% year-over-year to $330006.7 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was $436974.4 (up 74.55% YoY) and the FY2023 annual result came in at $436974.4, up 74.55% from the prior year.
• Income from Non-Controlling Interests climbed to $330006.7 in Q3 2023 per PRQR's latest filing, from $18207.3 in the prior quarter.
• Over the last five years, Income from Non-Controlling Interests for PRQR reached as high as $330006.7 in Q3 2023 and fell as low as -$99002.0 in Q1 2019.
• A 5-year average of $13775.2 and a median of -$9103.6 in 2020 frame the typical range for Income from Non-Controlling Interests.
• Annual changes were most pronounced in 2019 — Income from Non-Controlling Interests plunged 218.27% — and 2022, when it jumped 3200.0%.
• Year by year, Income from Non-Controlling Interests stood at -$51207.9 in 2019, then soared by 75.56% to -$12517.5 in 2020, then tumbled by 72.73% to -$21621.1 in 2021, then soared by 84.21% to -$3413.9 in 2022, then soared by 9766.67% to $330006.7 in 2023.
• According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $330006.7, $18207.3, and $88760.4 for Q3 2023, Q2 2023, and Q1 2023 respectively.